UBS has recently initiated Clover Health Investments Corp (CLOV) stock to Neutral rating, as announced on October 7, 2024, according to Finviz. Earlier, on February 2, 2022, Cowen had raised the stock ...
The heavy selling pressure might have exhausted for Clover Health Investments (CLOV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall ...
A downtrend has been apparent in Clover Health Investments, Corp. (CLOV) lately. While the stock has lost 23.1% over the past ...
On Friday, Clover Health Investments Corp (CLOV) stock saw a decline, ending the day at $3.41 which represents a decrease of $-0.26 or -7.08% from the prior close of $3.67. The stock opened at $3.69 ...
Clover Health Investments, Corp. (NASDAQ:CLOV – Get Free Report) saw unusually large options trading on Thursday. Stock investors purchased 62,471 call options on the company. This represents an ...
Canaccord analyst Richard Close raised the firm’s price target on Clover Health (CLOV) to $4.20 from $3.20 and keeps a Buy rating on the ...
Clover Health Investments, Corp. CLOV delivered a loss per share of 2 cents in the third quarter of 2024, narrower than the ...
Option chain shows key data for Clover Health Investments's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market ...
Pre-earnings options volume in Clover Health (CLOV) is normal with calls leading puts 11:2. Implied volatility suggests the market is ...
Good afternoon, everyone. Joining me on our call today to discuss the company’s third quarter 2024 results are Andrew Toy, Clover Health’s Chief Executive Officer; and Peter Kuipers, the company’s ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Clover Health's pivot to profitability over growth has led to significant earnings improvements. See why I rate CLOV stock as ...